Literature DB >> 8006372

Hemispheric processing and methylphenidate effects in attention-deficit hyperactivity disorder.

M A Malone1, J R Kershner, J M Swanson.   

Abstract

To advance our understanding of attention-deficit hyperactivity disorder and medication effects we draw upon the evidence for (1) a neurotransmitter imbalance between norepinephrine and dopamine in attention-deficit hyperactivity disorder and (2) an asymmetric neural control system that links the dopaminergic pathways to left hemispheric processing and links the noradrenergic pathways to right hemispheric processing. It appears that attention-deficit hyperactivity disorder may involve a bihemispheric dysfunction characterized by reduced dopaminergic and excessive noradrenergic functioning. In turn, favorable medication effects may be mediated by a restoration in neurotransmitter balance and by increased control over the allocation of attentional resources between hemispheres.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8006372     DOI: 10.1177/088307389400900216

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  3 in total

1.  Transgenic mice bearing a human mutant thyroid hormone beta 1 receptor manifest thyroid function anomalies, weight reduction, and hyperactivity.

Authors:  R Wong; V V Vasilyev; Y T Ting; D I Kutler; M C Willingham; B D Weintraub; S Cheng
Journal:  Mol Med       Date:  1997-05       Impact factor: 6.354

2.  Increased glutamate-stimulated norepinephrine release from prefrontal cortex slices of spontaneously hypertensive rats.

Authors:  V A Russell; T M Wiggins
Journal:  Metab Brain Dis       Date:  2000-12       Impact factor: 3.584

3.  Psychostimulants for the Treatment of Comorbid Post-traumatic Stress Disorder (PTSD) in a Patient With Attention-Deficit/Hyperactivity Disorder (ADHD): A Case Report and Literature Summary.

Authors:  Claudette Barreto; Ana Vila Irigoyen; Olga Lopez; Leonard Gralnik
Journal:  Cureus       Date:  2022-08-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.